Fortrea Holdings (FTRE) EPS (Weighted Average and Diluted) (2022 - 2026)
Fortrea Holdings (FTRE) reported EPS (Weighted Average and Diluted) of -$0.25 for Q1 2026, up 96.0% on a YoY basis from -$0.13 in Q1 2025, and up 10.71% quarter-over-quarter from -$0.28 in Q4 2025.
Fortrea Holdings (FTRE) EPS (Weighted Average and Diluted) (2022 - 2026) Analysis & Trends
Fortrea Holdings has reported EPS (Weighted Average and Diluted) for 5 years, with the latest figure at -$0.25 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 96.0% year-over-year to -$0.25; the trailing twelve-month figure through Mar 2026 stood at -$4.84 (up 39.88% YoY), and the FY2025 full-year result was -$10.81, down 256.77% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.25, up from -$0.28 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $0.75 in Q2 2022, with the low at -$6.25 in Q1 2025.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.78 across 5 years, with a median of -$0.19 in 2024.
- Annual changes were most pronounced in 2024 — EPS (Weighted Average and Diluted) slumped 1088.89% — and 2026, when it jumped 96.0%.
- Fortrea Holdings' EPS (Weighted Average and Diluted) stood at $0.29 in 2022, then tumbled by 289.66% to -$0.55 in 2023, then soared by 92.73% to -$0.04 in 2024, then plunged by 600.0% to -$0.28 in 2025, then climbed by 10.71% to -$0.25 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.25 (Q1 2026), -$0.28 (Q4 2025), and -$0.17 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Fortrea Holdings | 1.43 Bn | 1.28 Bn | 123.60 Mn | -0.25 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.25 |
| Dec 31, 2025 | -0.28 |
| Sep 30, 2025 | -0.17 |
| Jun 30, 2025 | -4.14 |
| Mar 31, 2025 | -6.25 |
| Dec 31, 2024 | -0.04 |
| Sep 30, 2024 | -0.21 |
| Jun 30, 2024 | -1.55 |
| Mar 31, 2024 | -0.89 |
| Dec 31, 2023 | -0.55 |
| Sep 30, 2023 | -0.16 |
| Jun 30, 2023 | 0.28 |
| Mar 31, 2023 | 0.09 |
| Dec 31, 2022 | 0.29 |
| Sep 30, 2022 | 0.68 |
| Jun 30, 2022 | 0.75 |